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Summary
Objective: We examined the effects of nonsteroidal anti-inﬂammatory drug (NSAID) and intra-articular injections of sodium hyaluronate (HA)
on cartilage degeneration in rabbit knee osteoarthritis (OA) model induced by partial meniscectomy.
Methods: Loxoprofen sodium (LOX) was used as the NSAID, administered p.o. once daily for 14 days at a dose of 4 mg/kg, starting from the
day of meniscectomy. Suvenyl (SVE) was used as the high molecular weight HA, injected intra-articularly into injured knee every 3 days from
the day of surgery. The effect on pain was assessed by an Incapacitance Tester, and the damage of cartilage was evaluated by visual as-
sessment and histopathology at 14 days after the surgery.
Results: Hind paw weight bearing on the injured paw decreased time-dependently in the control group. In other three groups, the de-
crease of hind paw weight distribution was suppressed, demonstrating an analgesic effect. Visible damage and histopathological ﬁndings
of cartilage degeneration were evident in the cartilages of the control group at day 14. In the SVE group, the damaged cartilage area
decreased and cartilage degeneration was ameliorated. In contrast, in the LOX group, the cartilage degeneration was augmented com-
pared with the control group. And, this exacerbated cartilage degeneration induced by LOX was reversed by the concomitant use of
SVE.
Conclusion: Our data show that the treatment with high molecular weight HA from earlier stage is strongly recommended to preserve the struc-
ture of cartilage.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA), one of the most common joint diseases,
is characterized by a slow degradation of cartilage for a long
time. OA of the hip and knee causes the chronic disability
because of the related pain and functional impairment,
which results from the involvement of large weight-bearing
joints. Currently available pharmacological therapies mainly
target palliation of pain and include analgesics, intra-articu-
lar therapy, and topical treatments1.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
widely used for the treatment of OA patients. Although
NSAIDs are useful for pain management, there are many
reports describing the possibility of accelerated disease
progression2e5. Huskisson et al. reported that indomethacin
increased the rate of radiological deterioration of joint space
in patients with OA of the knee compared with placebo2. In
another paper, Reijman reported that long-term use of diclo-
fenac might induce accelerated progression of hip and knee
OA in the Rotterdam study using 1695 patients5.
In general, intra-articular injections of sodium hyaluronate
(HA) are used for more serious pain compared with
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2006.54NSAIDs. Several clinical trials show that HA therapy is
a reasonable treatment for patients with mild-to-moderate
OA of knee, who are suffering from ongoing pain or are un-
able to tolerate the other conservative treatments or joint re-
placement operation6e8. The purpose of intra-articular HA
therapy is to make up the loss of viscoelasticity of synovial
ﬂuid due to the inﬂammation and to protect the degradation
of cartilage. Suvenyl (SVE) is a high molecular weight HA.
Regarding viscoelastic properties, it is thought that higher
molecular weight HA is superior to lower molecular weight
HA9.
In this study, we examined the effects of NSAIDs and
a high molecular weight HA on cartilage degeneration as-
sessed by macroscopic and histological evaluation and
pain of joint assessed by hind paw weight distribution in
the rabbit OA model. In addition, we studied the combina-
tion effect of both drugs.
Method
REAGENTS
SVE (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan)was
used as a high molecular weight HA. Its weight average mo-
lecular weight is 2700 kDa (viscosity average molecular
weight is 1900 kDa). It was produced by fermentationmethod
using the lactobacillus Streptcoccus equi and prepared as
a formulation in physiological saline at the concentration of
10 mg/mL. Loxoprofen monosodium (monosodium 2-[4-
(2-oxocyclopentyl-methyl) phenyl] propionate dehydrate)3
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Fig. 1. Protocol.(LOX) is the most popular NSAID available in Japan10. It was
purchased from CHEMIX Inc. (Yokohama, Kanagawa,
Japan). Water and saline for injection were obtained from
Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima,
Japan.
ANIMALS
Male 13-week-old Kbl:JW rabbits were purchased from
Kitayama Labes, Co., Ltd. (Ina, Nagano, Japan). Animals
were kept in Fiber Reinforced Plastics cage (350W
527D 350H mm) individually in a room at 22 3C
and 55 20% humidity. The animals were fed RC4 pellet
type laboratory animal food (Oriental Yeast Co., Ltd.,
Tokyo, Japan) through a stainless steel pellet feeder,
with a daily limit of ca. 150 g/day, and tap water was given
freely.
EXPERIMENTAL OA MODEL
The experimental OA model was prepared according to
the modiﬁed Colombo’s method reported by Kikuchi
et al.11. Under anesthesia by using ketamine hydrochloride
(Sankyo Yell Yakuhin Co., Ltd., Tokyo, Japan) and xyla-
zine (Beyer Medical Ltd., Tokyo, Japan) in combination,
the rabbit’s left knee joint was incised aseptically about
2 cm down the lateral aspect of the patella to expose
and cut the lateral collateral ligament. The end of the pop-
liteus muscle tendon was incised to expose the lateral me-
niscus, and then the lateral meniscus was resected in the
midsection for 3.0 to 4.0 mm. The subdermal muscular
layer and skin were sewed by knotted suture and ca.
0.2 mL ampicillin (Meiji Seika Kaisha, Ltd., Tokyo, Japan)
was injected intramuscularly into the thigh. The partial me-
niscectomy was conducted just before administration of
the testing drugs.EXPERIMENTAL DESIGN
Rabbits, which underwent partial meniscectomy in left
knee joint, were divided into four groups. The control group
was administered water orally, and intra-articularly injected
with saline. The LOX group was administered LOX orally,
and intra-articularly injected with saline. The SVE group
was administered water orally, and intra-articularly injected
with SVE. The LOXþSVE group was administered LOX
orally, and intra-articularly injected with SVE. Each group
consisted of eight animals.
LOX and water were orally administered daily from the
day of meniscectomy for 14 days. The ﬁrst dose was admin-
istered immediately after the surgery. The dosage of LOX
was 4 mg/kg, which demonstrated anti-inﬂammatory ef-
fect12, and the volume administered orally was 5 mL/kg
for both LOX and water. SVE and saline were intra-articu-
larly injected ﬁve times on days 0, 3, 6, 9, and 12 at
a dose of 0.1 mL/kg to the meniscectomized left cavity of
the knee joint, using a 1 mL injection syringe (Terumo
Corp., Tokyo, Japan) and a 26G injection needle (Terumo
Corp.) as previously reported11. See Fig. 1 for details.
OBSERVATION OF GENERAL STATUS AND BODY WEIGHT
MEASUREMENT
The general status was observed once a day, before the
oral administration of water or LOX. The body weight was
measured at days 0 (post surgery), 3, 6, 9, 12, and 14 (last
day). After experiment, stomach was taken out from all
animals and abnormalities were examined macroscopically.
PAIN ASSESSMENT
Hind paw weight distribution was measured by Incapaci-
tance Tester (Linton Instrumentation, Norfolk, England)
which independently measures the weight bearing to eachTable I
Body weight gain
Group n Days after operation
0 3 6 9 12 14
Control 8 2.84 0.04 2.84 0.04 2.87 0.04 2.87 0.05 2.93 0.05 2.96 0.05
SVE 8 2.88 0.05 2.85 0.06 2.90 0.05 2.92 0.06 2.94 0.06 3.00 0.06
LOX 8 2.86 0.06 2.83 0.05 2.86 0.05 2.89 0.05 2.93 0.05 2.95 0.05
LOXþSVE 8 2.82 0.04 2.79 0.04 2.83 0.04 2.87 0.04 2.88 0.04 2.93 0.04
Body weight (kg) was measured at indicated days. The data indicate the mean SE of eight animals. The SVE group, the LOX group, or the
LOXþSVE group was compared with the control group using unpaired t test.
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Fig. 2. Weight distribution on left hind paw. Weight distribution on left hind paw was measured by Incapacitance Tester at 1e2 h after LOX
administration. Each column and vertical line indicates the mean and SE of eight animals. The signiﬁcant difference (or statistical analysis)
between the value of each point and the value of Pre were analyzed using paired t test (*P< 0.05).hind paw. Measurement was performed three times and %
weight distribution of left hind paw was calculated by the fol-
lowing formula:
% weight distribution of left hind paw
¼

left weight
ðright weightþ left weightÞ

 100
The value of % weight distribution on left hind paw per
measurement was deﬁned as the mean of three calcula-
tions of the % weight distribution on left hind paw.
In order to acclimatize the animals to Incapacitance Tes-
ter, all animals were placed in the holder and immobilized
for 5 s daily for 7 days from the day of arrival. And then, be-
fore the day of starting the administration, the animals were
Hollow area
White rough area
Fig. 3. Picture of a typical damaged joint. The damaged lesion con-
sists of a white rough area having a coarse surface of the cartilage,
and a hollow area with a pit in the cartilage tissue. Left lateral con-
dyle of femur was covered by plastic wrap, and the area of damage
was measured by tracing the area of injury. The traced paper was
scanned into the computer, and then the area was measured by us-
ing the general-purpose image processing software.stratiﬁed according to the value of % weight distribution on
left hind paw.
The % weight distribution on both hind paws were mea-
sured the day before surgery, and days 1, 4, 7, and 13 after
surgery. It was measured once after 1e2 h after oral
administration.
VISUAL ASSESSMENT OF THE DAMAGED AREA
After sacriﬁce, resected left lateral condyle of femur was
covered by plastic wrap, and the area of damage was mea-
sured by tracing the area of injury. The original traced paper
was scanned into the computer, the damaged area was
painted black, and then the surface area of the damaged
area was measured by using the general-purpose image
processing software ‘‘Magical IP’’ (Magical Art, Ltd., Tokyo,
Japan). The measurement was conducted in a blinded fash-
ion to avoid any subjective bias.
ASSESSMENT OF THE JOINT CARTILAGE LESION
The left femoral condyle was resected and immediately
ﬁxed in 10% formalin buffer (pH 7.4) containing 0.5% of ce-
tylpyridinium chloride. The samples were decalciﬁed in 10%
ethylene diaminetetraacetic acid (EDTA) (pH 7.4) and em-
bedded in parafﬁn. A parafﬁn embedded cross-section of
the femoral condyle was prepared at a point 5 mm distant
from the end of the popliteus muscle tendon, and stained
by Safranin-O (staining using Safranin-O, fast green, and
iron hematoxylin).
Histopathological evidence of cartilage degeneration was
assessed according to the scoring system by Kikuchi et al.
and eight items, namely loss of superﬁcial layer, erosion of
cartilage, ﬁbrillation and/or ﬁssures, loss of proteoglycan,
disorganization of chondrocytes, loss of chondrocytes, ex-
posure of subchondral bone, and cluster formation that
were assessed at four levels graded from 1 to 411.
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Fig. 4. Damaged area of joint cartilage. Each column and vertical line indicates the mean and SE of eight animals. The unpaired t test was
used for the statistical analysis. The SVE group or the LOX group was compared with the control group (*P< 0.05). The LOXþ SVE group
was compared with the LOX group (#P< 0.05).In addition, the Safranin-O unstained area, which indi-
cates a loss of proteoglycans from the joint cartilage, was
measured using a 20 eyepiece micrometer (1 mm divided
into 100 reticules).
STATISTICAL ANALYSIS
Statistical analysis of body weight gain, visible damaged
area, and Safranin-O unstained area was performed by un-
paired t test. The % weight distribution on left hind paw was
analyzed by paired t test. For the grade scores for the indi-
vidual items of the histopathological assessment, the Manne
Whitney U test was conducted. The signiﬁcance level for
each analysis was set as 5%.
Results
OBSERVATION OF GENERAL STATUS AND BODY WEIGHT
During the administration period, there were no abnor-
malities observed in any of the groups. The change of
body weight during the administration period was shown
in Table I. All groups had a similar trend compared with
the control group. In addition, there were no macroscopical
abnormalities of stomach.
PERCENT WEIGHT DISTRIBUTION ON LEFT HIND PAW
The change of % weight distribution on left hind paw dur-
ing the administration period was shown in Fig. 2. The con-
trol group showed a time dependent decrease in the
change of % weight distribution on left hind paw, and the
values (meanSE) at days 4, 7, and 13 were
46.6 0.7%, 42.9 1.1%, and 40.9 2.0%, respectively.
In contrast, for the SVE group, the LOX group and the
LOXþ SVE group, the values prior to the surgery were gen-
erally maintained at all measurement points of time.
DAMAGED AREA OF THE JOINT CARTILAGE
The damaged lesion consisted of a white rough area hav-
ing a coarse surface of the cartilage, and a hollow area with
a pit in the cartilage tissue (Fig. 3). The damaged areas in
each group are shown in Fig. 4. In the control group, the
white rough area (mean  SE) was 17.37  1.14 mm2
and the hollow area was 9.87  0.72 mm2, but in the LOXgroup, the white rough area was 21.20 0.90 mm2 and
the hollow area was 13.69 0.80 mm2, both of them being
signiﬁcantly higher than the control group. The LOXþ SVE
group had a signiﬁcantly lower area for both the white
rough area and hollow area (16.47 1.46 mm2 and
7.95 0.70 mm2, respectively). The SVE group compared
with the control group had a lower but not signiﬁcant value
for the rough white area (15.39 1.74 mm2), and a signiﬁ-
cantly lower value for the hollow area (6.44 0.77 mm2).
HISTOPATHOLOGICAL FINDINGS OF THE JOINT CARTILAGE
The degree of damage of each of the lesions in the joint
cartilage of the lateral femoral condyle is shown in Fig. 5.
The LOX group had a higher score for all of the assessment
items, and the signiﬁcant differences compared with the
control group were observed for loss of superﬁcial layer
and ﬁbrillation and/or ﬁssures. The LOXþSVE group had
a lower score (alleviation of cartilage degeneration) com-
pared with the LOX group for all of the assessment items,
and a signiﬁcant difference was observed in loss of super-
ﬁcial layer, ﬁbrillation and/or ﬁssures, disorganization of
chondrocytes, loss of chondrocytes, and cluster formation.
The SVE group had a lower score for all items except clus-
ter formation compared with the control group, and the sig-
niﬁcant improvements were observed for ﬁbrillation and/or
ﬁssures, disorganization of chondrocytes, and loss of
chondrocytes.
The LOX group had an increased Safranin-O unstained
area compared with the control group, however, the
LOXþ SVE group and the SVE group had a greater Safra-
nin-O stained area compared with the LOX group (Figs. 6
and 7).
Discussion
In the present study, the effects of oral LOX and intra-ar-
ticular SVE were examined in the experimental rabbit OA
model of partial meniscectomy of the knee, and the follow-
ing ﬁndings were shown: (1) Pain increased with the pro-
gression of cartilage degeneration of the knee joint, but it
was alleviated by oral LOX administration or intra-articular
SVE injection. (2) Intra-articular SVE injection apparently in-
hibited cartilage degeneration. (3) Oral LOX administration
exacerbated cartilage degeneration, but such exacerbation
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Fig. 5. Histopathological score. Histopathological assessment was conducted according to the assessment criteria by Kikuchi et al. Each col-
umn and vertical line indicates the mean and SE of eight animals. For the statistical analysis, the ManneWhitney U test was used. The SVE
group or the LOX group was compared with the control group (*P< 0.05). The LOXþSVE group was compared with the LOX group
(#P< 0.05).was suppressed by concomitant use of intra-articular SVE
(Figs. 5 and 6).
Pain control is one of the main targets of OA therapy. In
this study, we measured weight distribution on injured hind
paw and normal paw as an analgesic effect by Incapaci-
tance Tester. It has been reported that an analgesic effect
of morphine and celecoxib could be assessed in this
system13 and this method is utilized for the evaluation of
anti-OA drugs and analgesic drugs14,15. Percent weight dis-
tribution on left hind paw measured by Incapacitance Tester
decreased in a time dependent manner in the control group.
This phenomenon was thought to be due to increased pain
induced by progression of cartilage degeneration of theknee joint. In contrast, in other three groups, % weight dis-
tribution on left hind paw was unchanged, suggesting anal-
gesic effects. This is a ﬁrst paper describing that HA
showed the analgesic effect assessed by weight distribution
on hind paw using Incapacitance Tester.
Our present study clearly showed that SVE showed pre-
ventive effect on cartilage destruction as well as an analge-
sic effect in rabbit OA model. HA is responsible for the
viscoelastic quality of synovial ﬂuid that acts as both a lubri-
cant and a shock absorber. However, since the increase in
small molecular weight HA in affected joint is observed
under inﬂammatory condition such as OA16, same pheno-
menon may occur in our model because inﬂammation
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played the preventive effect on cartilage destruction by
maintaining viscoelastic properties of synovial ﬂuid in
rabbit.
In addition, there are lots of reports describing the biolog-
ical activities of HA other than viscoelastic property. HA
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Fig. 6. Safranin-O unstained area. Safranin-O unstained area was
measured using a 20 eyepiece micrometer and counting the ret-
icules. Each column and vertical line indicates the mean and SE of
eight animals. The unpaired t test was used for the statistical anal-
ysis. The SVE group or the LOX group was compared with the con-
trol group (*P< 0.05). The LOXþ SVE group was compared with
the LOX group (#P< 0.05).inhibited the production of matrix metalloproteinases which
induced cartilage matrix degradation17e19, promoted matrix
biosynthesis20e22, and prevented the induction of apoptosis
of chondrocytes23. These effects participate in the structure
modifying effect. Moreover, HA suppressed the production
of inﬂammatory cytokines and inﬂammatory mediators, sug-
gesting anti-inﬂammatory effect18,19,24e26. These various
activities of HA may also be involved in the preventive effect
of SVE on the cartilage destruction.
NSAIDs are used as a ﬁrst line drug for the treatment
of OA. However, we here showed that LOX augmented
a visible damaged area and the exacerbation of cartilage
degeneration compared with the control group. This phe-
nomenon supports the clinical ﬁndings that NSAIDs accel-
erate progression of OA2e5. It is not likely that this result
is due to the toxicity of LOX, because gastrointestinal ab-
normality was not observed in LOX-treated animals after
experiment. Although the precise reason for this phenom-
enon is not clear, it could be postulated that normal
movement became possible by the analgesic effect,
which may lead to increased abrasion at the joint surface
without the improvement of viscoelastic property of syno-
vial ﬂuid.
In addition, inhibition of matrix biosynthesis of the joint
cartilage by NSAIDs has been reported27,28, implying a pos-
sibility of direct effect of NSAIDs on the chondrocytes to in-
hibit cartilage formation. By the combination use of SVE, the
exacerbation of cartilage degeneration induced by LOX was
inhibited. This result suggests that the combination of HA
has an advantage to prevent NSAID-induced cartilage de-
struction, when the use of NSAID is unavoidable because
of severe inﬂammation.
In conclusion, we propose that the treatment with high
molecular weight HA from earlier stage is stronglyFig. 7. Histology of cartilage. The injured femoral condyle was ﬁxed in 10% formalin buffer (pH 7.4) containing 0.5% of cetylpyridinium chloride.
After decalciﬁcation, the femoral condyle section was stained by Safranin-O. The pictures are representative of each group.
549Osteoarthritis and Cartilage Vol. 15, No. 5recommended because there is a possibility that NSAID ex-
acerbates cartilage degeneration in OA.
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